Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / IMMX - Immix Biopharma rises 7% on patient dosing in phase 1b/2a IMX-110 monotherapy trial

IMMX - Immix Biopharma rises 7% on patient dosing in phase 1b/2a IMX-110 monotherapy trial

Immix Biopharma Inc.
  • Immix Biopharma ( NASDAQ: IMMX ) is trading ~7% higher premarket after it announced patient dosing in an ongoing Phase 1b/2a IMX-110 monotherapy clinical trial.
  • The company expects IMX-110 clinical trial data to be released on a rolling basis beginning in Q1 2023.
  • Once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110, under the trial.
  • The company is also testing IMX-110 as a combination therapy with Beigene/Novartis anti-PD-1 tislelizumab.

For further details see:

Immix Biopharma rises 7% on patient dosing in phase 1b/2a IMX-110 monotherapy trial
Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...